Cargando…

Identification of potential diagnostic and prognostic biomarkers for papillary thyroid microcarcinoma (PTMC) based on TMT-labeled LC–MS/MS and machine learning

OBJECTIVES: To explore the molecular mechanisms underlying aggressive progression of papillary thyroid microcarcinoma and identify potential biomarkers. METHODS: Samples were collected and sequenced using tandem mass tag-labeled liquid chromatography–tandem mass spectrometry. Differentially expresse...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, J., Mi, L., Ran, B., Sui, C., Zhou, L., Li, F., Dionigi, G., Sun, H., Liang, N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10185636/
https://www.ncbi.nlm.nih.gov/pubmed/36418670
http://dx.doi.org/10.1007/s40618-022-01960-x
_version_ 1785042399461900288
author Li, J.
Mi, L.
Ran, B.
Sui, C.
Zhou, L.
Li, F.
Dionigi, G.
Sun, H.
Liang, N.
author_facet Li, J.
Mi, L.
Ran, B.
Sui, C.
Zhou, L.
Li, F.
Dionigi, G.
Sun, H.
Liang, N.
author_sort Li, J.
collection PubMed
description OBJECTIVES: To explore the molecular mechanisms underlying aggressive progression of papillary thyroid microcarcinoma and identify potential biomarkers. METHODS: Samples were collected and sequenced using tandem mass tag-labeled liquid chromatography–tandem mass spectrometry. Differentially expressed proteins (DEPs) were identified and further analyzed using Mfuzz and protein–protein interaction analysis (PPI). Parallel reaction monitoring (PRM) and immunohistochemistry (IHC) were performed to validate the DEPs. RESULTS: Five thousand, two hundred and three DEPs were identified and quantified from the tumor/normal comparison group or the N1/N0 comparison group. Mfuzz analysis showed that clusters of DEPs were enriched according to progressive status, followed by normal tissue, tumors without lymphatic metastases, and tumors with lymphatic metastases. Analysis of PPI revealed that DEPs interacted with and were enriched in the following metabolic pathways: apoptosis, tricarboxylic acid cycle, PI3K-Akt pathway, cholesterol metabolism, pyruvate metabolism, and thyroid hormone synthesis. In addition, 18 of the 20 target proteins were successfully validated with PRM and IHC in another 20 paired validation samples. Based on machine learning, the five proteins that showed the best performance in discriminating between tumor and normal nodules were PDLIM4, ANXA1, PKM, NPC2, and LMNA. FN1 performed well in discriminating between patients with lymph node metastases (N1) and N0 with an AUC of 0.690. Finally, five validated DEPs showed a potential prognostic role after examining The Cancer Genome Atlas database: FN1, IDH2, VDAC1, FABP4, and TG. Accordingly, a nomogram was constructed whose concordance index was 0.685 (confidence interval: 0.645–0.726). CONCLUSIONS: PDLIM4, ANXA1, PKM, NPC2, LMNA, and FN1 are potential diagnostic biomarkers. The five-protein nomogram could be a prognostic biomarker. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s40618-022-01960-x.
format Online
Article
Text
id pubmed-10185636
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-101856362023-05-17 Identification of potential diagnostic and prognostic biomarkers for papillary thyroid microcarcinoma (PTMC) based on TMT-labeled LC–MS/MS and machine learning Li, J. Mi, L. Ran, B. Sui, C. Zhou, L. Li, F. Dionigi, G. Sun, H. Liang, N. J Endocrinol Invest Original Article OBJECTIVES: To explore the molecular mechanisms underlying aggressive progression of papillary thyroid microcarcinoma and identify potential biomarkers. METHODS: Samples were collected and sequenced using tandem mass tag-labeled liquid chromatography–tandem mass spectrometry. Differentially expressed proteins (DEPs) were identified and further analyzed using Mfuzz and protein–protein interaction analysis (PPI). Parallel reaction monitoring (PRM) and immunohistochemistry (IHC) were performed to validate the DEPs. RESULTS: Five thousand, two hundred and three DEPs were identified and quantified from the tumor/normal comparison group or the N1/N0 comparison group. Mfuzz analysis showed that clusters of DEPs were enriched according to progressive status, followed by normal tissue, tumors without lymphatic metastases, and tumors with lymphatic metastases. Analysis of PPI revealed that DEPs interacted with and were enriched in the following metabolic pathways: apoptosis, tricarboxylic acid cycle, PI3K-Akt pathway, cholesterol metabolism, pyruvate metabolism, and thyroid hormone synthesis. In addition, 18 of the 20 target proteins were successfully validated with PRM and IHC in another 20 paired validation samples. Based on machine learning, the five proteins that showed the best performance in discriminating between tumor and normal nodules were PDLIM4, ANXA1, PKM, NPC2, and LMNA. FN1 performed well in discriminating between patients with lymph node metastases (N1) and N0 with an AUC of 0.690. Finally, five validated DEPs showed a potential prognostic role after examining The Cancer Genome Atlas database: FN1, IDH2, VDAC1, FABP4, and TG. Accordingly, a nomogram was constructed whose concordance index was 0.685 (confidence interval: 0.645–0.726). CONCLUSIONS: PDLIM4, ANXA1, PKM, NPC2, LMNA, and FN1 are potential diagnostic biomarkers. The five-protein nomogram could be a prognostic biomarker. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s40618-022-01960-x. Springer International Publishing 2022-11-23 2023 /pmc/articles/PMC10185636/ /pubmed/36418670 http://dx.doi.org/10.1007/s40618-022-01960-x Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Original Article
Li, J.
Mi, L.
Ran, B.
Sui, C.
Zhou, L.
Li, F.
Dionigi, G.
Sun, H.
Liang, N.
Identification of potential diagnostic and prognostic biomarkers for papillary thyroid microcarcinoma (PTMC) based on TMT-labeled LC–MS/MS and machine learning
title Identification of potential diagnostic and prognostic biomarkers for papillary thyroid microcarcinoma (PTMC) based on TMT-labeled LC–MS/MS and machine learning
title_full Identification of potential diagnostic and prognostic biomarkers for papillary thyroid microcarcinoma (PTMC) based on TMT-labeled LC–MS/MS and machine learning
title_fullStr Identification of potential diagnostic and prognostic biomarkers for papillary thyroid microcarcinoma (PTMC) based on TMT-labeled LC–MS/MS and machine learning
title_full_unstemmed Identification of potential diagnostic and prognostic biomarkers for papillary thyroid microcarcinoma (PTMC) based on TMT-labeled LC–MS/MS and machine learning
title_short Identification of potential diagnostic and prognostic biomarkers for papillary thyroid microcarcinoma (PTMC) based on TMT-labeled LC–MS/MS and machine learning
title_sort identification of potential diagnostic and prognostic biomarkers for papillary thyroid microcarcinoma (ptmc) based on tmt-labeled lc–ms/ms and machine learning
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10185636/
https://www.ncbi.nlm.nih.gov/pubmed/36418670
http://dx.doi.org/10.1007/s40618-022-01960-x
work_keys_str_mv AT lij identificationofpotentialdiagnosticandprognosticbiomarkersforpapillarythyroidmicrocarcinomaptmcbasedontmtlabeledlcmsmsandmachinelearning
AT mil identificationofpotentialdiagnosticandprognosticbiomarkersforpapillarythyroidmicrocarcinomaptmcbasedontmtlabeledlcmsmsandmachinelearning
AT ranb identificationofpotentialdiagnosticandprognosticbiomarkersforpapillarythyroidmicrocarcinomaptmcbasedontmtlabeledlcmsmsandmachinelearning
AT suic identificationofpotentialdiagnosticandprognosticbiomarkersforpapillarythyroidmicrocarcinomaptmcbasedontmtlabeledlcmsmsandmachinelearning
AT zhoul identificationofpotentialdiagnosticandprognosticbiomarkersforpapillarythyroidmicrocarcinomaptmcbasedontmtlabeledlcmsmsandmachinelearning
AT lif identificationofpotentialdiagnosticandprognosticbiomarkersforpapillarythyroidmicrocarcinomaptmcbasedontmtlabeledlcmsmsandmachinelearning
AT dionigig identificationofpotentialdiagnosticandprognosticbiomarkersforpapillarythyroidmicrocarcinomaptmcbasedontmtlabeledlcmsmsandmachinelearning
AT sunh identificationofpotentialdiagnosticandprognosticbiomarkersforpapillarythyroidmicrocarcinomaptmcbasedontmtlabeledlcmsmsandmachinelearning
AT liangn identificationofpotentialdiagnosticandprognosticbiomarkersforpapillarythyroidmicrocarcinomaptmcbasedontmtlabeledlcmsmsandmachinelearning